Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial
Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial
复制标题
DOI：
10.1111/vox.12411
复制
发表时间：
2016-10-01
期刊：
影响因子：
2.7
通讯作者：
Slichter, S. J.
中科院分区：
文献类型：
--
作者：
Hess, J. R.;Trachtenberg, F. L.;Slichter, S. J.
背景与目的血小板同种异体免疫和血小板输注无效是血小板输注治疗的并发症。作为迄今为止最大的预防性血小板治疗的前瞻性随机试验，PLADO试验提供了一个分析这两个问题的机会。材料与方法对PLADO患者的记录进行检查，以寻找血小板同种异体免疫的证据，定义为人类白细胞抗原I类群反应性抗体(PRA)增加到20%，以及临床难治，定义为连续两次
Background and Objectives Platelet alloimmunization and refractoriness to platelet transfusion are complications of platelet transfusion therapy. The platelet dose (PLADO) trial, as the largest prospective randomized trial of prophylactic platelet therapy to date, afforded an opportunity to analyse these two issues.Materials and Methods PLADO patient records were examined for evidence of platelet alloimmunization, defined as an increase in HLA Class I panel-reactive antibodies (PRA) to >= 20%, and clinical refractoriness, defined as two consecutive